An antibiotic therapeutic composition or method of treatment includes administering a beta-
lactamase inhibitor in combination with a beta-
lactam antibiotic. The beta-
lactamase inhibitor can be a boronic-acid, a boronic-ester beta-
lactamase inhibitor, carboxyl-group beta-lactamase inhibitors,
halogen-terminated heterocyclic group beta-lactamase inhibitors, or any pharmaceutically acceptable salts thereof. In combination, the beta-lactamase inhibitors and beta-
lactam antibiotics can inhibit the growth of
bacteria that are resistant to the beta-
lactam antibiotics alone. According to additional embodiments, the effectiveness of various combinations of compounds including various
antibiotics and compounds selected from the group consisting of 5-Carboxythiophene-2-
boronic acid pinacol ester, 5-Carboxy-2-fluorophenylboronic Acid, 3-Amino-5-carboxylphenylboronic acid, 5-Carboxy-2-chlorophenylboronic acid, 3-Carboxy-2-fluorophenylboronic acid, 5- dehydroxyboryl-2-thiophenecarboxylic acid, and 5-Borono-2-chlorobenzoic acid is demonstrated. Particularly, when combined with certain antibiotics, each of these compounds demonstrates enhanced effectiveness against
bacteria and bacterial infections even where the
bacteria are known to be resistant to the beta-lactam antibiotics.